Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioblastoma 2Ependymoma 2Central Nervous System Neoplasms 2Typical Teratoid Rhabdoid Tumor 1Pinealoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neoplasms, Neuroepithelial 1Meningioma 1Medulloblastoma 1Gliosarcoma 1Glioma 1Choroid Plexus Neoplasms 1Astrocytoma 1

Interventions

interferon gamma-1b 1Vincristine 1Valproic Acid 1Thiotepa 1Peripheral Blood Stem Cell Transplantation 1Oncolytic Virotherapy 1ONC206 1Melphalan 1Interferon-gamma 1Immunotherapy 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Busulfan 1Bone Marrow Transplantation 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neuroectodermal Tumors × ONC206 × Clear all
NCT04541082 2025-12-18

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Jazz Pharmaceuticals

Phase 1 Recruiting
102 enrolled
CNSSarcoma

Typical Teratoid Rhabdoid Tumor, Astrocytoma, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Oligodendroglioma, Pinealoma, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡